A groundbreaking analysis of how well animal studies predict human safety will lead to reduced animal testing and better clinical results for patients, it is hoped.
As part of pharmaphorum’s ‘eye-on-innovation’ interview series, Paul Tunnah speaks to Bayer’s Chief Marketing Officer Pharmaceuticals, Sebastian Guth, on his views on how the synergy of pharma
Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
